

ASX Announcement

Medibio Limited – 21 DEC 2016



Change of Australian Corporate Office

Effective immediately, the Australian Registered Office address has changed to:

Suite 302, Level 3
17 Castlereagh Street
Sydney NSW 2000
Phone: +61 2 9299 9580
Fax: +61 2 9299 9501

The mailing address remains as GPO Box 4492 Sydney 2001 and the phone, fax and email addresses are unchanged.

- ENDS -

For further information please contact:

Robert Lees
Company Secretary
Phone: +61 2 9299 9580

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Located in Melbourne (Vic) Medibio is listed on the Australian Securities Exchange Ltd.